Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480703

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480703

Hereditary Angioedema

PUBLISHED:
PAGES: 196 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 14850

Add to Cart

Description

Table of Contents

Global Hereditary Angioedema Market to Reach $5 Billion by 2030

The global market for Hereditary Angioedema estimated at US$2.9 Billion in the year 2023, is expected to reach US$5 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Selective Bradykinin B2 Receptor Antagonists segment is estimated at 6.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $889.5 Million, While China is Forecast to Grow at 7.1% CAGR

The Hereditary Angioedema market in the U.S. is estimated at US$889.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$849.3 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.5% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 46 Featured) -

  • BioCryst Pharmaceuticals, Inc.
  • CSL Ltd.
  • iBio, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Pharming Group NV
  • Shire PLC
Show more
Product Code: MCP16460

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Hereditary Angioedema - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hospital pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Retail pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Hereditary Angioedema Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for C1 Esterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for C1 Esterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for C1 Esterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Selective Bradykinin B2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Selective Bradykinin B2 Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Kallikrein Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Kallikrein Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Kallikrein Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Subcutaneous Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Subcutaneous Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Subcutaneous Injections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Hereditary Angioedema by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hereditary Angioedema Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Hereditary Angioedema by Route Of Administration - Subcutaneous Injections, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous Injections, Intravenous and Oral for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Hereditary Angioedema by Distribution Channel - Retail pharmacies, Hospital pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Retail pharmacies, Hospital pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!